David Lowrance
Director of Finance/CFO chez SAVARA INC.
Fortune : 2 M $ au 30/04/2024
Profil
David L.
Lowrance is currently the Director at Washington Biotechnology & Biomedical Association since 2014 and the Chief Financial & Administrative Officer at Savara, Inc. since 2017.
Previously, he worked as the Head-Finance at BorgWarner, Inc., Senior Accountant at Ernst & Young LLP, Chief Financial Officer & Vice President at Cumberland Pharmaceuticals, Inc. from 2003 to 2011, Chief Financial Office at Aravas, Inc., Chief Financial Officer & Treasurer at Edgemont Pharmaceuticals LLC from 2014 to 2016, Chief Financial Officer & Secretary at Acucela, Inc. from 2011 to 2014, and Chief Financial Officer at Kubota Pharmaceutical Holdings Co. Ltd.
He obtained his undergraduate degree from the University of Georgia in 1989.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SAVARA, INC.
0,25% | 28/12/2023 | 342 355 ( 0,25% ) | 2 M $ | 30/04/2024 |
Postes actifs de David Lowrance
| Sociétés | Poste | Début |
|---|---|---|
| SAVARA INC. | Director of Finance/CFO | 27/04/2017 |
| Washington Biotechnology & Biomedical Association | Director/Board Member | 01/07/2014 |
Anciens postes connus de David Lowrance
| Sociétés | Poste | Fin |
|---|---|---|
Edgemont Pharmaceuticals LLC
 Edgemont Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Edgemont Pharmaceuticals LLC develops and provides products for psychiatric disorders. The company was founded by Douglas A. Saltel in 2008 and is headquartered in Austin, TX. | Director of Finance/CFO | 01/10/2016 |
| ACUCELA INC | Director of Finance/CFO | 19/09/2014 |
| CUMBERLAND PHARMACEUTICALS INC. | Director of Finance/CFO | 04/04/2011 |
Aravas, Inc.
 Aravas, Inc. Pharmaceuticals: MajorHealth Technology Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX. | Director of Finance/CFO | - |
| KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Director of Finance/CFO | - |
Formation de David Lowrance
| University of Georgia | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BORGWARNER INC. | Producer Manufacturing |
| CUMBERLAND PHARMACEUTICALS INC. | Health Technology |
| KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Health Technology |
| SAVARA INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Acucela, Inc.
 Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
| Washington Biotechnology & Biomedical Association | |
Edgemont Pharmaceuticals LLC
Edgemont Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Edgemont Pharmaceuticals LLC develops and provides products for psychiatric disorders. The company was founded by Douglas A. Saltel in 2008 and is headquartered in Austin, TX. | Health Technology |
Aravas, Inc.
Aravas, Inc. Pharmaceuticals: MajorHealth Technology Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX. | Health Technology |
